EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development and validation of a combined diagnostic model for prostate cancer integrating MRI parameters with p504s, CK5/6, and Ki-67 expression

Qingchang Ren, Jialong Gu, Nankang Lu

Open Life Sciences · 23.01.2026 · 21 (1)

DOI: 10.1515/biol-2025-1244 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Life Sciences, online erschienen am 23.01.2026. Verfasst von Qingchang Ren und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The Second People's Hospital, Wuhu, Wuhu, 241000, Anhui, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to develop and validate a diagnostic model for prostate cancer (PCa) by integrating magnetic resonance imaging (MRI) parameters with the immunohistochemical expression of p504s, CK5/6, and Ki-67. A total of 448 patients undergoing prostate needle biopsy were included and randomly allocated into training (70 %) and validation (30 %) cohorts. Clinical data, MRI findings, and biomarker expression levels were analyzed. Multivariate logistic regression identified independent predictors, which were used to construct a diagnostic nomogram. Compared to controls, PCa patients had significantly higher PSA levels, lower f-PSA/t-PSA ratios, a greater frequency of palpable nodules, higher CC/C ratios, lower ADC values, increased p504s and Ki-67 positivity, and reduced CK5/6 expression. Seven variables were ultimately identified as independent predictors for the model. The resulting nomogram demonstrated excellent discrimination, with an area under the curve (AUC) of 0.971 in the training set and 0.977 in the validation set. It significantly outperformed a model using clinical indicators alone. This combined MRI-biomarker model shows high diagnostic accuracy for PCa and could potentially aid clinical decision-making and reduce unnecessary biopsies. External validation is required prior to clinical application.

Schlagwörter

Stichwörter der Autor:innen

Ki-67MRI parameterscytokeratin 5/6prostate cancerα-Methylacyl-CoA racemase

Autor:innen und Institutionen

  • Department of Radiology, The Second People's Hospital, Wuhu, Wuhu, 241000, Anhui, China.
  • Huashan Hospital Fudan University, Shanghai, 200040, Shanghai, China.
  • Department of Radiology, The First Affiliated Hospital of Hainan Medical College, Haikou, 570102, Hainan, China.

Zitieren

APA

Ren, Q., Gu, J., & Lu, N. (2026). Development and validation of a combined diagnostic model for prostate cancer integrating MRI parameters with p504s, CK5/6, and Ki-67 expression. Open Life Sciences, 21(1). https://doi.org/10.1515/biol-2025-1244

Vancouver

Ren Q, Gu J, Lu N. Development and validation of a combined diagnostic model for prostate cancer integrating MRI parameters with p504s, CK5/6, and Ki-67 expression. Open Life Sciences. 2026;21(1). doi:10.1515/biol-2025-1244

BibTeX
@article{Ren2026,
  author = {Ren, Qingchang and Gu, Jialong and Lu, Nankang},
  title = {Development and validation of a combined diagnostic model for prostate cancer integrating MRI parameters with p504s, CK5/6, and Ki-67 expression},
  journal = {Open Life Sciences},
  year = {2026},
  volume = {21},
  number = {1},
  doi = {10.1515/biol-2025-1244}
}
Kostenlos starten →